UNSPSC 51161728: Doxapram hydrochloride anhydrous

This classification denotes a cns stimulant C24H30N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FB8713U6DM, chemically known as (+/-)-1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinone monohydrochloride, but more generally known as doxapram hydrochloride anhydrous, which bears US NIH Compound Identifier 64647. Most nations, for tariff and trade purposes, schedule doxapram hydrochloride anhydrous under HS 29349990 and SITC 51579.

As of Q4 2014, DOXAPRAM HYDROCHLORIDE ANHYDROUS remains US FDA's Preferred Term for this commodity. SMILES: CCN1CC(C(C1=O)(C2CCCCC2)C3CCCCC3)CCN4CCOCC4.CL.

UNSPSC 51161728 Doxapram hydrochloride anhydrous, a Commodity code, does not align with the state and local procurement opportunities currently tagged under it. The recent solicitations show activity in naloxone procurement, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic pharmaceuticals through cooperative purchasing — none of which involve doxapram or its specific respiratory-stimulant therapeutic use. The mismatch suggests either a classification error in the source data or that doxapram is being procured at minimal volume under broader pharmaceutical or emergency medical supply codes. Based on the opportunities presented, this code shows little relevant recent state and local activity.

The issuing bodies in the related pharmaceutical and pharmacy-services opportunities span county health departments (Seminole County, Florida; Hall County, Georgia), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances (MMCAP, administered by Minnesota Department of Administration). Recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems (response deadline July 26, 2023), Hall County's RFQ/P for on-site pharmacy services at a county health center (response deadline June 4, 2026), the Texas HHS RFI on direct-to-manufacturer prescription programs (issued April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers (response deadline March 26, 2026). Geographic activity clusters in the Southeast and through multistate cooperative vehicles serving Oregon and multiple participating jurisdictions, though the doxapram code itself does not directly support these opportunities.